Explore News By Topic
09/29/2020
Depend® brand partners with Mark Teixeira to announce Stand Strong for Men’s Health™ campaign benefitting the Prostate Cancer Foundation
NEENAH, Wis., Sept. 29, 2020 — In honor of Prostate Cancer Awareness Month, the Depend brand announced today its partnership with Major League Baseball (MLB) All-Star Mark Teixeira and the Prostate Cancer Foundation (PCF) for the Stand Strong for Men’s Health™ campaign, an initiative to destigmatize male incontinence and celebrate... Read More
08/18/2020
The Prostate Cancer Foundation and Actor Harry Lennix Challenge Americans to “Eat It To Beat It” During Prostate Cancer Awareness Month
LOS ANGELES, Calif., August 18, 2020 – The Prostate Cancer Foundation (PCF) challenges Americans to show their support for men affected by prostate cancer by taking a simple challenge to eat 30 healthy foods during Prostate Cancer Awareness Month in September. Actor and PCF celebrity ambassador Harry Lennix joins PCF’s “Eat... Read More
07/21/2020
The Prostate Cancer Foundation and Robert F. Smith Announce New Effort to Address Health Disparities for African American Men
LOS ANGELES, Calif., July 21, 2020 – The Prostate Cancer Foundation (PCF) and Robert F. Smith, founder, chairman and CEO of Vista Equity Partners, announce a new effort to reduce deaths from prostate cancer, one of the largest health disparities facing African American men today. “As African American men are... Read More
07/20/2020
Prostate Cancer Metastasis Linked to Revival of Dormant Molecular Program
When prostate cancer progresses to a more-dangerous metastatic state, it does so by resurrecting dormant molecular mechanisms that had guided the fetal development of the prostate gland but had been subsequently switched off, say scientists from Dana-Farber Cancer Institute. The study, an international collaboration with The Netherlands Cancer Institute, was published in Nature... Read More
07/07/2020
The Prostate Cancer Foundation Collaboration with Pan-Cancer Consortium Clarifies and Promotes Consistent Use of Common Terms for Biomarker and Germline Genetic Testing
LOS ANGELES, Calif., July 7, 2020 — The Prostate Cancer Foundation (PCF) has collaborated with a consortium of 41 leading patient advocacy organizations, professional societies and industry partners to publish a white paper detailing recommendations for the use of testing terminology in precision medicine for patient education throughout the cancer... Read More
06/09/2020
New Recommendations Offer Guidance for Clinicians & Patients on Implementing Genetic Testing for Prostate Cancer
PHILADELPHIA — An international panel of experts led by researchers and thought-leaders at the Sidney Kimmel Cancer Center – Jefferson Health (SKCC) and the Department of Urology at Jefferson have published the first multidisciplinary, consensus-driven prostate cancer genetic implementation framework for the precision medicine era. The consensus framework is a... Read More
05/30/2020
ASCO 2020: Blood Test Predicts Response to Prostate Cancer Treatment
A new blood test can predict how well men with advanced prostate cancer will respond to treatment and could replace some of the existing methods used to characterise and track the disease. The non-invasive test is less painful and cheaper than tissue biopsies and can help pick out men who... Read More
05/20/2020
Lynparza approved in the US for HRR gene-mutated metastatic castration-resistant prostate cancer
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been approved in the US for patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). The approval by the US Food and Drug Administration... Read More
05/15/2020
Rubraca® (Rucaparib) Approved In The U.S. As Monotherapy Treatment For Patients With BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (MCRPC) Who Have Been Treated With Androgen Receptor-Directed Therapy And A Taxane-Based Chemotherapy
Rubraca is the first PARP inhibitor approved in a prostate cancer setting Accelerated approval based on objective response rate (ORR) and duration of response (DOR) data from the TRITON2 clinical trial i 44% ORR (95% CI 31, 57) and median DOR not evaluable (95% CI 6.4, NE, range in... Read More
05/15/2020
VA Launches Clinical Trial for Veterans with COVID-19 Based on Prostate Cancer Drug
WASHINGTON — Today, the U.S. Department of Veterans Affairs (VA) began a new clinical trial to test a Food and Drug Administration-approved prostate cancer drug as a potential treatment for male Veterans with COVID-19. In a double-blind randomized controlled trial, VA scientists will compare the drug degarelix (trade name Firmagon) to a placebo... Read More